COMPANY:

Takeda

P3 | "These data demonstrate that fruquintinib consistently improved OS vs P in pts with previously treated mCRC with and without liver mets at baseline. Fruquintinib is an effective and tolerable treatment option for pts with mCRC regardless of liver mets.Previously presented at ESMO 2024; Final Publication Number: 520P; Rocio Garcia-Carbonero et al. Reused with permission."

P3 | "Pts had received prior chemotherapy, anti-VEGF therapy and, if RAS wild type, anti-EGFR therapy; and had prior exposure to trifluridine/tipiracil (TAS-102) and/or regorafenib. Longer-term OS and PFS rates at 6 and 9 mos were higher with F vs P in the FRESCO-2 ITT pop. A higher proportion of pts with OS ≥10 mos had no liver mets and ECOG PS 0 at BL vs the ITT pop. The safety profile of F in pts with OS ≥10 mos was consistent with the ITT pop"

"While its efficacy is wellestablished in chronic-phase CML, the real-world data on its use in relapsed/refractory (r/r) B-ALL andblast-phase CML (CML-BP), particularly among patients who are ponatinib-refractory or those withcomplex resistance mutations remains underexplored.MethodsWe performed a retrospective analysis of adult patients with either B-ALL or CML-BP who receivedasciminib at our institution between November 1, 2021, and March 30, 2025. While higher dosing may be effectivein overcoming specific mutations, it could also contribute to the emergence of additional resistancemutations. These findings underscore the need for prospective studies to optimize dosing strategies,sequencing, and resistance monitoring."

"Introduction:Brentuximab vedotin (BV) and nivolumab (N) have resulted in significant progress in the treatment ofadvanced-stage Hodgkin lymphoma (AS-HL). The SWOG 1826 trial demonstrated a progression-freesurvival (PFS) and safety benefit with frontline N-AVD (doxorubicin, vinblastine, and dacarbazine)compared to BV-AVD; however, real-world data are limited...This large real-world multicenter study demonstrates that response rates and 1-yr survival outcomes withN-AVD and BV-AVD are similar to the published SWOG 1826 trial (N-AVD vs BV-AVD: 1-yr PFS: 94% vs 86%,Herrera et al. 2024). Increased cardiovascular AEs, dose reductions/omissions and neuropathy with BV-AVD indicate better tolerability with N-AVD; however, the higher rate of febrile neutropenia andinfections in comparison to SWOG 1826 in N-AVD pts suggests that growth factor prophylaxis may bebeneficial in select high-risk subgroups."

P3 | N=120 | Completed | Sponsor: Baxalta now part of Shire | Active, not recruiting ➔ Completed

"BostonGene...announced that it will collaborate with Takeda on immuno-oncology focused research studies. This partnership aims to identify key molecular drivers and predictive markers for treatment efficacy and adverse effects with the primary goal of advancing clinical solutions and improving patient outcomes....Takeda will leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials to enhance trial design, improve indication selection and identify biomarker signatures for response and toxicity. BostonGene will perform sophisticated multiomic analytics using proprietary computational platforms on clinical and laboratory data provided by Takeda. Additionally, BostonGene will conduct extensive bioinformatics analysis on flow cytometry, RNA-seq and proteomics data."

"Geneseeq was invited by Takeda Pharmaceutical...to participate in the launch ceremony of the Takeda Lung Cancer Diagnosis and Treatment Alliance to sign off on the two companies’ strategic partnership. The companies jointly stated that they will actively respond to the overall requirements of China’s 'Precision Medicine Plan', advance lung cancer precision medicine development, standardize precision diagnostics in clinical care, and improve patient access to personalized medicine."